{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:26:42Z","timestamp":1792567602173,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41375-026-02931-4","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:32:37Z","timestamp":1776857557000},"page":"1392-1400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Gene expression-based dissemination score predicts early spread and poor outcomes in multiple myeloma"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2892-1816","authenticated-orcid":false,"given":"Arwa","family":"Bohra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7972-3556","authenticated-orcid":false,"given":"Surendra","family":"Dasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-8453","authenticated-orcid":false,"given":"Saurabh","family":"Zanwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-969X","authenticated-orcid":false,"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-364X","authenticated-orcid":false,"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Timm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0203","authenticated-orcid":false,"given":"Francis","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1792-5822","authenticated-orcid":false,"given":"Dragan","family":"Jevremovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"2931_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00527-y","volume":"11","author":"R Bansal","year":"2021","unstructured":"Bansal R, Rakshit S, Kumar S. Extramedullary disease in multiple myeloma. Blood Cancer J. 2021;11:1\u20138.","journal-title":"Blood Cancer J"},{"key":"2931_CR2","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.3390\/cancers14061430","volume":"14","author":"J-J Garc\u00e9s","year":"2022","unstructured":"Garc\u00e9s J-J, San-Miguel J, Paiva B. Biological characterization and clinical relevance of circulating tumor cells: opening the Pandora\u2019s box of multiple myeloma. Cancers. 2022;14:1430.","journal-title":"Cancers"},{"key":"2931_CR3","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.4149\/neo_2022_220428N463","volume":"69","author":"J-X Tang","year":"2022","unstructured":"Tang J-X, Zhang J-H, Zhou K-B, Li W-T, Wang J-Y, Li Q, et al. Association between BRAF expression in circulating tumor cells and the clinical features of patients with multiple myeloma. Neoplasma. 2022;69:1228\u201336.","journal-title":"Neoplasma"},{"key":"2931_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1365-2141.1991.tb04383.x","volume":"78","author":"MS Hamilton","year":"1991","unstructured":"Hamilton MS, Ball J, Bromidge E, Franklin IM. Surface antigen expression of human neoplastic plasma cells includes molecules associated with lymphocyte recirculation and adhesion. Br J Haematol. 1991;78:60\u201365.","journal-title":"Br J Haematol"},{"key":"2931_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/ijlh.13387","volume":"43","author":"I Klimien\u0117","year":"2021","unstructured":"Klimien\u0117 I, Radzevi\u010dius M, Matuzevi\u010dien\u0117 R, Sinkevi\u010d-Belliot K, Ku\u010dinskien\u0117 ZA, Pe\u010deli\u016bnas V. Adhesion molecule immunophenotype of bone marrow multiple myeloma plasma cells impacts the presence of malignant circulating plasma cells in peripheral blood. Int J Lab Hematol. 2021;43:403\u20138.","journal-title":"Int J Lab Hematol"},{"key":"2931_CR6","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.celrep.2015.06.059","volume":"12","author":"AM Roccaro","year":"2015","unstructured":"Roccaro AM, Mishima Y, Sacco A, Moschetta M, Tai Y-T, Shi J, et al. CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal transition-like transcriptional activation. Cell Rep. 2015;12:622\u201335.","journal-title":"Cell Rep"},{"key":"2931_CR7","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1038\/s41375-020-0883-0","volume":"34","author":"J-J Garc\u00e9s","year":"2020","unstructured":"Garc\u00e9s J-J, Bretones G, Burgos L, Vald\u00e9s-Mas R, Puig N, Cedena M-T, et al. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. Leukemia. 2020;34:3007\u201318.","journal-title":"Leukemia"},{"key":"2931_CR8","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","volume":"56","author":"S Skerget","year":"2024","unstructured":"Skerget S, Penaherrera D, Chari A, Jagannath S, Siegel DS, Vij R, et al. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat Genet. 2024;56:1878\u201389.","journal-title":"Nat Genet"},{"key":"2931_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41416-020-01178-9","volume":"124","author":"SV Vasaikar","year":"2021","unstructured":"Vasaikar SV, Deshmukh AP, den Hollander P, Addanki S, Kuburich NA, Kudaravalli S, et al. EMTome: a resource for pan-cancer analysis of epithelial-mesenchymal transition genes and signatures. Br J Cancer. 2021;124:259\u201369.","journal-title":"Br J Cancer"},{"key":"2931_CR10","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/s41375-025-02653-z","volume":"39","author":"A Bohra","year":"2025","unstructured":"Bohra A, Hassan R, Zanwar S, Jevremovic D, Olteanu H, Gonsalves WI, et al. Peripheral blood flow cytometry-based definition of plasma cell leukemia. Leukemia. 2025;39:2039\u201341.","journal-title":"Leukemia"},{"key":"2931_CR11","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, Corre J, D\u2019Agostino M, Kaiser MF, et al. International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J Clin Oncol. 2025;43:2739\u201351.","journal-title":"J Clin Oncol"},{"key":"2931_CR12","doi-asserted-by":"crossref","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol 2022;40:3406\u201318.","DOI":"10.1200\/JCO.22.02228"},{"key":"2931_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47793-5","volume":"15","author":"M Binder","year":"2024","unstructured":"Binder M, Szalat RE, Talluri S, Fulciniti M, Avet-Loiseau H, Parmigiani G, et al. Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells, leading to transcriptional changes. Nat Commun. 2024;15:4139.","journal-title":"Nat Commun"},{"key":"2931_CR14","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","volume":"24","author":"G Ledergor","year":"2018","unstructured":"Ledergor G, Weiner A, Zada M, Wang S-Y, Cohen YC, Gatt ME, et al. Single-cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat Med. 2018;24:1867\u201376.","journal-title":"Nat Med"},{"key":"2931_CR15","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1158\/1078-0432.CCR-19-0694","volume":"26","author":"D Ryu","year":"2020","unstructured":"Ryu D, Kim SJ, Hong Y, Jo A, Kim N, Kim H-J, et al. Alterations in the transcriptional programs of myeloma cells and the microenvironment during extramedullary progression affect proliferation and immune evasion. Clin Cancer Res. 2020;26:935\u201344.","journal-title":"Clin Cancer Res"},{"key":"2931_CR16","doi-asserted-by":"publisher","first-page":"E2393","DOI":"10.1073\/pnas.1604351113","volume":"113","author":"A Vandenbon","year":"2016","unstructured":"Vandenbon A, Dinh VH, Mikami N, Kitagawa Y, Teraguchi S, Ohkura N, et al. Immuno-navigator, a batch-corrected coexpression database, reveals cell type-specific gene networks in the immune system. Proc Natl Acad Sci USA. 2016;113:E2393\u20132402.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2931_CR17","doi-asserted-by":"publisher","first-page":"W234","DOI":"10.1093\/nar\/gkz240","volume":"47","author":"G Zhou","year":"2019","unstructured":"Zhou G, Soufan O, Ewald J, Hancock REW, Basu N, Xia J. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis. Nucleic Acids Res. 2019;47:W234\u2013W241.","journal-title":"Nucleic Acids Res"},{"key":"2931_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01081-z","volume":"14","author":"MJ Rees","year":"2024","unstructured":"Rees MJ, Mammadzadeh A, Bolarinwa A, Elhaj ME, Bohra A, Bansal R, et al. Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma. Blood Cancer J. 2024;14:122.","journal-title":"Blood Cancer J"},{"key":"2931_CR19","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1182\/blood-2025-825","volume":"146","author":"A Afrough","year":"2025","unstructured":"Afrough A, Pasvolsky O, Zanwar S, Gaballa M, Sannareddy A, Dima D, et al. Talquetamab outcomes in relapsed\/refractory myeloma with extramedullary and paraskeletal soft tissue plasmacytomas. Blood. 2025;146:825.","journal-title":"Blood"},{"key":"2931_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMoa2514752","volume":"394","author":"S Kumar","year":"2025","unstructured":"Kumar S, Mateos M-V, Ye JC, Atrash S, Magen H, Quach H, et al. Dual targeting of extramedullary myeloma with talquetamab and teclistamab. N Engl J Med. 2025;394:51\u201361.","journal-title":"N Engl J Med"},{"key":"2931_CR21","doi-asserted-by":"publisher","first-page":"e798","DOI":"10.1016\/S2352-3026(25)00176-0","volume":"12","author":"L Jin","year":"2025","unstructured":"Jin L, Gu S, Ruan Q, Lu J, Qiang W, He H, et al. GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2025;12:e798\u2013e807.","journal-title":"Lancet Haematol"},{"key":"2931_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104710","volume":"211","author":"K Thangaretnam","year":"2025","unstructured":"Thangaretnam K, Islam MO, Lv J, El-Rifai A, Perloff A, Soutto HL, et al. WEE1 inhibition in cancer therapy: Mechanisms, synergies, preclinical insights, and clinical trials. Crit Rev Oncol Hematol. 2025;211:104710.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2931_CR23","first-page":"244","volume":"110","author":"J Kr\u00fcger","year":"2024","unstructured":"Kr\u00fcger J, Obenaus M, Blau IW, Hoser D, Vaegler M, Rauschenbach H, et al. A phase I study of MAGE-A1-targeted T1367 T-cell receptor-based cell therapy in patients with advanced multiple myeloma. Haematologica. 2024;110:244\u201350.","journal-title":"Haematologica"},{"key":"2931_CR24","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1182\/blood.2019000578","volume":"134","author":"Z Ren","year":"2019","unstructured":"Ren Z, Ahn JH, Liu H, Tsai Y-H, Bhanu NV, Koss B, et al. PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation. Blood. 2019;134:1176\u201389.","journal-title":"Blood"},{"key":"2931_CR25","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.3390\/cancers12082206","volume":"12","author":"Y Fujibayashi","year":"2020","unstructured":"Fujibayashi Y, Isa R, Nishiyama D, Sakamoto-Inada N, Kawasumi N, Yamaguchi J, et al. Aberrant BUB1 overexpression promotes mitotic segregation errors and chromosomal instability in multiple myeloma. Cancers. 2020;12:2206.","journal-title":"Cancers"},{"key":"2931_CR26","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.81184","volume":"12","author":"M Farrell","year":"2023","unstructured":"Farrell M, Fairfield H, Karam M, D\u2019Amico A, Murphy CS, Falank C, et al. Targeting the fatty acid binding proteins disrupts multiple myeloma cell cycle progression and MYC signaling. eLife. 2023;12:e81184.","journal-title":"eLife"},{"key":"2931_CR27","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/s41375-024-02210-0","volume":"38","author":"S Grasedieck","year":"2024","unstructured":"Grasedieck S, Panahi A, Jarvis MC, Borzooee F, Harris RS, Larijani M, et al. Redefining high-risk multiple myeloma with an APOBEC\/Inflammation-based classifier. Leukemia. 2024;38:1172\u20137.","journal-title":"Leukemia"},{"key":"2931_CR28","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1038\/s41388-022-02398-4","volume":"41","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Sun F, Thornton K, Jing X, Dong J, Yun G, et al. FOXM1 regulates glycolysis and energy production in multiple myeloma. Oncogene. 2022;41:3899\u2013911.","journal-title":"Oncogene"},{"key":"2931_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01230-y","volume":"15","author":"AK Simhal","year":"2025","unstructured":"Simhal AK, Firestone RS, Oh JH, Avutu V, Norton L, Hultcrantz M, et al. High WEE1 expression is independently linked to poor survival in multiple myeloma. Blood Cancer J. 2025;15:22.","journal-title":"Blood Cancer J"},{"key":"2931_CR30","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.bcmd.2012.01.006","volume":"48","author":"D Chiron","year":"2012","unstructured":"Chiron D, Ma\u00efga S, Descamps G, Moreau P, Le Gouill S, Marionneau S, et al. Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. Blood Cells Mol Dis. 2012;48:247\u201353.","journal-title":"Blood Cells Mol Dis"},{"key":"2931_CR31","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3109\/10428194.2014.911863","volume":"56","author":"P Wu","year":"2015","unstructured":"Wu P, Walker BA, Broyl A, Kaiser M, Johnson DC, Kuiper R, et al. A gene expression-based predictor for high-risk myeloma treated with intensive therapy and autologous stem cell rescue. Leuk Lymphoma. 2015;56:594\u2013601.","journal-title":"Leuk Lymphoma"},{"key":"2931_CR32","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1158\/1535-7163.MCT-12-0721","volume":"11","author":"J Moreaux","year":"2012","unstructured":"Moreaux J, R\u00e8me T, Leonard W, Veyrune J-L, Requirand G, Goldschmidt H, et al. Development of gene expression\u2013based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors. Mol Cancer Ther. 2012;11:2685\u201392.","journal-title":"Mol Cancer Ther"},{"key":"2931_CR33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/10428194.2020.1832659","volume":"62","author":"A Reale","year":"2021","unstructured":"Reale A, Khong T, Mithraprabhu S, Savvidou I, Hocking J, Bergin K, et al. TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing. Leuk Lymphoma. 2021;62:337\u201347.","journal-title":"Leuk Lymphoma"},{"key":"2931_CR34","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1182\/bloodadvances.2020002578","volume":"5","author":"BC Lipchick","year":"2021","unstructured":"Lipchick BC, Utley A, Han Z, Moparthy S, Yun DH, Bianchi-Smiraglia A, et al. The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma. Blood Adv. 2021;5:1933\u201346.","journal-title":"Blood Adv"},{"key":"2931_CR35","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1182\/blood-2019-129818","volume":"134","author":"S Okabe","year":"2019","unstructured":"Okabe S, Tanaka Y, Moriyama M, Gotoh A. Targeting glycolysis in multiple myeloma: novel strategies in the treatment of proteasome inhibitor-resistant cells in hypoxic conditions. Blood. 2019;134:4344.","journal-title":"Blood"},{"key":"2931_CR36","doi-asserted-by":"publisher","first-page":"6584","DOI":"10.1182\/blood-2023-188004","volume":"142","author":"J Qiao","year":"2023","unstructured":"Qiao J, Liu Y, Nian L, Wang C, Yu M, Zhang W, et al. The resistance mechanism to BET-protac in multiple myeloma. Blood. 2023;142:6584.","journal-title":"Blood"},{"key":"2931_CR37","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1158\/1541-7786.MCR-21-0681","volume":"20","author":"T Moser-Katz","year":"2022","unstructured":"Moser-Katz T, Gavile CM, Barwick BG, Lee KP, Boise LH. PDZ proteins SCRIB and DLG1 regulate myeloma cell surface CD86 expression, growth, and survival. Mol Cancer Res. 2022;20:1122\u201336.","journal-title":"Mol Cancer Res"},{"key":"2931_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-024-01133-4","volume":"14","author":"M Evers","year":"2024","unstructured":"Evers M, St\u00fchmer T, Schreder M, Steinbrunn T, Rudelius M, Jundt F, et al. Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma. Blood Cancer J. 2024;14:1\u201311.","journal-title":"Blood Cancer J"},{"key":"2931_CR39","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1200\/JCO.23.01277","volume":"42","author":"F Maura","year":"2024","unstructured":"Maura F, Rajanna AR, Ziccheddu B, Poos AM, Derkach A, Maclachlan K, et al. Genomic classification and individualized prognosis in multiple myeloma. J Clin Oncol. 2024;42:1229\u201340.","journal-title":"J Clin Oncol"},{"key":"2931_CR40","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1200\/JCO-25-01733","volume":"44","author":"F Maura","year":"2026","unstructured":"Maura F, Bergsagel PL, Ziccheddu B, Kumar S, Maclachlan K, Derkach A, et al. Genomics defines malignant transformation in myeloma precursor conditions. J Clin Oncol. 2026;44:188\u201399.","journal-title":"J Clin Oncol"},{"key":"2931_CR41","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JD Shaughnessy","year":"2007","unstructured":"Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276\u201384.","journal-title":"Blood"},{"key":"2931_CR42","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nm.2174","volume":"16","author":"F Chibon","year":"2010","unstructured":"Chibon F, Lagarde P, Salas S, P\u00e9rot G, Brouste V, Tirode F, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med. 2010;16:781\u20137.","journal-title":"Nat Med"},{"key":"2931_CR43","doi-asserted-by":"publisher","first-page":"e66361","DOI":"10.1371\/journal.pone.0066361","volume":"8","author":"T-H Chung","year":"2013","unstructured":"Chung T-H, Mulligan G, Fonseca R, Chng WJ. A novel measure of chromosome instability can account for prognostic differences in multiple myeloma. PLoS ONE. 2013;8:e66361.","journal-title":"PLoS ONE"},{"key":"2931_CR44","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/ng1861","volume":"38","author":"SL Carter","year":"2006","unstructured":"Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet. 2006;38:1043\u20138.","journal-title":"Nat Genet"},{"key":"2931_CR45","doi-asserted-by":"publisher","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","volume":"52","author":"C Knox","year":"2024","unstructured":"Knox C, Wilson M, Klinger CM, Franklin M, Oler E, Wilson A, et al. DrugBank 6.0: the DrugBank knowledgebase for 2024. Nucleic Acids Res. 2024;52:D1265\u2013D1275.","journal-title":"Nucleic Acids Res"},{"key":"2931_CR46","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3390\/cancers16040756","volume":"16","author":"N Merjaneh","year":"2024","unstructured":"Merjaneh N, Hajjar M, Lan Y-W, Kalinichenko VV, Kalin TV. The promise of combination therapies with FoxM1 inhibitors for cancer treatment. Cancers. 2024;16:756.","journal-title":"Cancers"},{"key":"2931_CR47","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1182\/blood.V122.21.532.532","volume":"122","author":"JJ Keats","year":"2013","unstructured":"Keats JJ, Craig DW, Liang W, Venkata Y, Kurdoglu A, Aldrich J, et al. Interim analysis of the Mmrf CoMmpass Trial, a longitudinal study in multiple myeloma relating clinical outcomes to genomic and immunophenotypic profiles. Blood. 2013;122:532\u2013532.","journal-title":"Blood"},{"key":"2931_CR48","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-09-2831","volume":"16","author":"NJ Dickens","year":"2010","unstructured":"Dickens NJ, Walker BA, Leone PE, Johnson DC, Brito JL, Zeisig A, et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin Cancer Res. 2010;16:1856\u201364.","journal-title":"Clin Cancer Res"},{"key":"2931_CR49","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1158\/1535-7163.MCT-24-1194","volume":"24","author":"J Ma","year":"2025","unstructured":"Ma J, Liu W, Li J, Kim D, Kim S, Levy A, et al. Azenosertib is a potent and selective WEE1 kinase inhibitor with broad antitumor activity across a range of solid tumors. Mol Cancer Ther. 2025;24:1171\u201385.","journal-title":"Mol Cancer Ther"},{"key":"2931_CR50","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1200\/JCO.21.01435","volume":"39","author":"JF Seligmann","year":"2021","unstructured":"Seligmann JF, Fisher DJ, Brown LC, Adams RA, Graham J, Quirke P, et al. Inhibition of WEE1 is effective in TP53- and RAS-mutant metastatic colorectal cancer: a randomized trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring. J Clin Oncol. 2021;39:3705\u201315.","journal-title":"J Clin Oncol"},{"key":"2931_CR51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1535-7163.MCT-22-0243","volume":"22","author":"W-K You","year":"2023","unstructured":"You W-K, Schuetz TJ, Lee SH. Targeting the DLL\/notch signaling pathway in cancer: challenges and advances in clinical development. Mol Cancer Ther. 2023;22:3\u201311.","journal-title":"Mol Cancer Ther"},{"key":"2931_CR52","first-page":"244","volume":"110","author":"J Kr\u00fcger","year":"2025","unstructured":"Kr\u00fcger J, Obenaus M, Blau IW, Hoser D, Vaegler M, Rauschenbach H, et al. A phase I study of MAGE-A1-targeted T1367 T-cell receptor-based cell therapy in patients with advanced multiple myeloma. Haematologica. 2025;110:244\u201350.","journal-title":"Haematologica"},{"key":"2931_CR53","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3390\/cancers17101703","volume":"17","author":"S Arora","year":"2025","unstructured":"Arora S, Scott AM, Janes PW. ADAM proteases in cancer: biological roles, therapeutic challenges, and emerging opportunities. Cancers. 2025;17:1703.","journal-title":"Cancers"},{"key":"2931_CR54","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1200\/JCO.2004.08.054","volume":"22","author":"JA Sparano","year":"2004","unstructured":"Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol. 2004;22:4683\u201390.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02931-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02931-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02931-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:54:06Z","timestamp":1782917646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02931-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2931"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02931-4","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with relevant guidelines and regulations and the Declaration of Helsinki. Archived biobanked bone marrow aspirate samples and clinical data from the Mayo Clinic validation cohort were analyzed under approval from the Mayo Clinic Institutional Review Board (521-93). Informed consent was obtained at the time of biobanking and was waived by the Institutional Review Board for this retrospective minimal-risk study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}